Background: LY3502970 (LY) is a novel, highly potent, orally bioavailable nonpeptide GLP-1 receptor agonist (RA) , and a potential alternative to injectable therapies or oral peptides whose absorption is affected by food or water intake. Objectives of this study were to evaluate safety, tolerability, pharmacokinetics (PK) , and pharmacodynamics (PD) of single and multiple doses of LY in healthy subjects.

Methods: This was a multi-part, randomized, double-blind, phase 1 study (NCT03929744) . In Part A, subjects received placebo or single-dose LY with 5 cohorts receiving escalating doses. In Part B, subjects received 4 weeks of daily placebo or repeated oral LY escalating weekly to 5 different final target doses. Overtly healthy adults 18-65 yrs old with body mass index 20-40 kg/m2 and A1c <6.5% were eligible.

Results: Of 133 subjects enrolled, 32 participated in Part A (mean age 43.4 yrs) and 60 participated in Part B (mean age 42.5 yrs) . There were no deaths or serious adverse events. Most common (occurring in ≥3 subjects) treatment-emergent adverse events in Part A were vomiting, nausea, and headache, and in Part B were nausea, headache, and constipation. PK was approximately proportional; mean Cmax in Part A was 1.4-14.9 ng/mL and mean t½ was 24.6-35.3 hrs across the dose range after single dose. In Part B, mean Cmax was 11.1-99.6 ng/mL and mean t½ was 48.1-67.5 hrs on Day 28 across the dose range. Single and repeated doses of LY decreased mean fasting glucose compared to baseline across Days 1-28. In Part B, significant reductions in body weight from baseline were observed after 4 weeks in 4 cohorts (except for the lowest dose) . Gastric emptying was delayed after initial LY dose but was no longer evident at Day 28.

Conclusion: This oral nonpeptide had safety and PD marker profiles similar to injectable GLP-1 RAs and PK enabling once daily dosing. These data support further clinical development.

Disclosure

E.J.Pratt: Employee; Eli Lilly and Company. X.Ma: Employee; Eli Lilly and Company, Stock/Shareholder; Eli Lilly and Company. R.Liu: Employee; Eli Lilly and Company. D.A.Robins: Employee; Eli Lilly and Company. K.Sloop: Employee; Eli Lilly and Company. C.Benson: None.

© 2022 by the American Diabetes Association
2022
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.